Kidney Compass: The PARASOL Initiative, with Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir

Author(s):

Brendon Neuen, MBBS, PhD,Shikha Wadhwani, MD, MS

Key Takeaways

Kidney Compass explores nephrology clinical trials, focusing on the PARASOL Initiative and FSGS.
The PARASOL Initiative investigates short-term biomarker changes as alternative endpoints for drug approval in FSGS.
Laura Mariani and Daniel Gale provide insights into the initiative's findings and implications for FSGS management.
The episode is divided into four sections, covering introductions, background, findings, and future directions.

This 4-part episode focuses on the PARASOL Initiative and the landscape of focal segmental glomerulosclerosis treatment.

Welcome to Kidney Compass: Navigating Clinical Trials!

Thumbnail from Kidney Compass episode spotlighting the PARASOL initiative. | Credit: HCPLive

Kidney Compass: The PARASOL Initiative

Part 1: Introductions

Part 2: PARASOL Background and FSGS Landscape

Part 3: PARASOL Findings and Implications for FSGS

Part 4: Future of PARASOL, FSGS Management

Produced by HCPLive Nephrology and hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, the director of Clinical trials in the Division of Nephrology and the vice chair of Clinical Research in the Department of Medicine at the University of Texas Medical Branch, Kidney Compass is your guide to exploring the latest developments in clinical trials and nephrology, from therapeutics advances to methodological and statistical approaches to analyzing clinical trials.

After a 3-episode run at the American Society of Nephrology's Kidney Week 2024, Neuen and Wadhwani are joined by special guests Laura Mariani, MD, MS, associate professor in the Division of Nephrology at the University of Michigan, and Daniel Gale, PhD, MB BChir, director of the UK-based RaDaR Registry and the St Peter's Chair of Nephrology at University College London, to explore the PARASOL Initiative and the landscape of focal segmental glomerulosclerosis (FSGS).

An international collaboration, the Proteinuria and GFR as Clinical Trial Endpoints in FSGS (PARASOL) Initiative was launched to investigate a link between short-term changes in biomarkers, like proteinuria and GFR, and long-term outcomes to support alternative endpoints for drug approval. Mariani co-chairs the project, which is led by the Michigan Kidney Translational Medicine Center and sponsored by NephCure, the International Society of Glomerular Disease, the Kidney Health Initiative, and the National Kidney Foundation.

For ease of viewing, we've divided this episode, which contains more than an hour of insights into the PARASOL Initiative and FSGS, into 4 sections and highlighted them above.

The entire, uninterrupted episode is available in an audio-only format on Spotify and Apple Podcasts.